Free Trial
NASDAQ:RENB

Lunai Bioworks 11/14/2023 Earnings Report

Lunai Bioworks logo
$1.54 +0.28 (+21.72%)
Closing price 09/30/2025
Extended Trading
$1.54 0.00 (0.00%)
As of 09/30/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lunai Bioworks EPS Results

Actual EPS
-$1.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lunai Bioworks Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lunai Bioworks Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lunai Bioworks Earnings Headlines

Lunai Bioworks (NASDAQ:RENB) Shares Up 12.2% - What's Next?
Lunai Bioworks unveils new corporate identity
Forget AI, This Will Be the Next Big Tech Breakthrough
After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...tc pixel
See More Lunai Bioworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lunai Bioworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lunai Bioworks and other key companies, straight to your email.

About Lunai Bioworks

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

View Lunai Bioworks Profile

More Earnings Resources from MarketBeat